Ted M. Dawson

Johns Hopkins University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Background Neuroinflammation and pathologic α-synuclein (α-syn) aggregation cooperate to drive dopaminergic neurodegeneration in Parkinson’s disease, but the glial receptors that couple extracellular α-syn to inflammatory cascades remain incompletely defined. Microglia express higher levels of lymphocyte activation gene 3 (Lag3) than neurons, yet the contribution of microglial Lag3 to α-syn recognition, glial crosstalk, and neurodegeneration is unknown. Methods Biochemical binding assays, live-cell imaging, cytokine profiling, and neuron–microglia–astrocyte co-culture paradigms were used to define Lag3-dependent α-syn preformed fibril (PFF) binding, uptake, and microglial activation. To interrogate in vivo function, microglia-specific Lag3 conditional knockout mice (Lag3 L/L -Cx3cr1 CreER ) and littermate controls received unilateral intrastriatal α-syn PFF injections, followed by histological, biochemical, and behavioral assessments of α-syn pathology, gliosis, nigrostriatal integrity, and motor performance. Results α-syn PFFs bound microglial Lag3 with high specificity and nanomolar affinity and required Lag3 for efficient fibril internalization and induction of proinflammatory cytokines. Microglial Lag3 deficiency markedly blunted α-syn PFF–evoked microglial activation, prevented cytokine-driven conversion of astrocytes into neurotoxic reactive A1 astrocytes, and abolished astrocyte-dependent neuronal death in vitro. In vivo, microglia-specific Lag3 deletion reduced cortical, striatal, and substantia nigra pS129 α-syn pathology, suppressed microgliosis and A1 astrocyte induction, preserved substantia nigra dopaminergic neurons and striatal dopamine transporter/tyrosine hydroxylase expression, and ameliorated α-syn PFF–induced motor deficits. Conclusions This study identifies microglial Lag3 as a key receptor linking extracellular α-syn PFF recognition to inflammatory amplification, neurotoxic reactive A1 astrocyte conversion, and dopaminergic neurodegeneration. Together with prior work on neuronal Lag3, these findings support a cell-type–specific dual-axis model in which neuronal Lag3 mediates α-syn propagation while microglial Lag3 drives glia-dependent neurotoxicity, positioning Lag3 as a promising precision therapeutic target in α-synucleinopathies.

Year:

2026

Astrocytes are increasingly recognized as key players in neurodegeneration 1–3 , yet the molecular mechanisms by which they drive disease remain elusive. Here, we uncover a fundamental pathway in which reactive astrocytes fuel neurodegeneration in α-synucleinopathies—including Dementia with Lewy bodies and Parkinson’s disease dementia—by acidifying the brain’s extracellular environment. We demonstrate that both human patient tissue and a gut-to-brain α-synuclein mouse model exhibit accumulation of reactive astrocytes and extracellular acidosis. Mechanistically, we show that astrocytic lysosomal exocytosis releases acidic contents, driving a drop in pH that activates neuronal acid-sensing ion channel 1a (ASIC1a), resulting in neuronal loss and behavioral decline. Blocking this pathway—either by inhibiting astrocytic lysosomal exocytosis or genetically or pharmacologically targeting neuronal ASIC1a—mitigates pathology and rescues neurodegenerative phenotypes in vivo. These findings provide a conceptual advance by establishing a mechanistic link between glial inflammation, acid-base homeostasis, and neuronal vulnerability, and suggest that targeting astrocyte-driven acidification or ASIC1a signaling could offer new avenues for disease modification in α-synucleinopathies.

Year:

2026

PARIS, a substrate of Parkin, accumulates in Parkinson’s disease and promotes disease progression. Here, we demonstrate that PARIS also contributes to Alzheimer’s disease by elevating STAT3 transcriptional activity, thereby inducing tau pathology, hippocampal atrophy, and glial activation. Genetic depletion of Paris reduced tau phosphorylation and cognitive decline in tauopathy mice, whereas neuron-specific PARIS overexpression caused tau accumulation, gliosis, and memory impairment. In contrast, astrocyte-specific overexpression did not induce pathology, indicating that PARIS acts in neurons to drive tau phosphorylation and glial activation. The pathological features induced by neuronal PARIS overexpression were rescued by STAT3 inhibition, demonstrating that PARIS–STAT3 signaling underlies these effects. Moreover, Paris knockout did not alter pathology in the amyloid-driven mouse model, highlighting specificity for tau pathology. Together, these findings reveal PARIS as a neuronal regulator of STAT3 signaling that exacerbates tau-mediated neurodegeneration and identify the PARIS–STAT3 pathway as a potential therapeutic target in Alzheimer’s disease.

Year:

2025

Parkinson’s disease (PD) is characterized by the accumulation of α-synuclein (α-syn) aggregates, which are thought to drive neurodegeneration in vulnerable neuronal populations, particularly within the dopaminergic nigrostriatal pathway. Here, we aimed to investigate the spatiotemporal relationship between α-syn aggregation and dopaminergic cell degeneration by developing an optimized analysis pipeline for efficient whole-brain mapping. We injected α-syn preformed fibrils (PFFs) into the substantia nigra pars compacta (SNc) of wild-type mice, using monomeric α-syn-injected mice as the control group. Aggregate propagation and dopaminergic degeneration were analyzed using antibodies against phosphorylated α-syn (pS129) and tyrosine hydroxylase, followed by brain clearing combined with high-resolution (<4 µm) light-sheet microscopy (LSM), coupled with automated pipeline data analysis. Whole-brain LSM mapping revealed dense somatic and neuritic phosphorylated α-syn aggregates within dopaminergic neurons of the SNc 12 weeks post-unilateral PFF injection, accompanied by significant loss of tyrosine hydroxylase-positive neurons and prion-like propagation of α-syn aggregates to anatomically connected brain regions, including the striatum. The distribution pattern of α-syn pathology visualized by LSM was validated by whole-brain immunohistochemical analysis of PFF-injected mouse brains. The 3D LSM approach introduced here uniquely captures the spatial organization and propagation of α-syn pathology and dopaminergic degeneration across interconnected brain networks.

Year:

2025

Poly(ADP-ribose) (PAR) polymerase-1 (PARP1) has been implicated in DNA damage responses and neuroinflammation in Alzheimer’s disease (AD), yet its role in amyloid-β (Aβ) pathology remains unclear. Here, we show that PARP1 activation drives Aβ pathology and neurodegeneration. Using a sensitive ELISA, we observed significantly elevated PAR levels in the cerebrospinal fluid (CSF) of patients with mild cognitive impairment (MCI) and AD compared to controls. In vitro , oligomeric Aβ 1-42 activated PARP1 and induced DNA damage, while genetic or pharmacological inhibition of PARP1 conferred neuroprotection. In vivo , PARP1 knockout in the 5XFAD mouse model of amyloidosis led to reduced amyloid plaque burden, preserved synaptic and neuronal integrity, attenuated glial activation and neuroinflammation, and rescued cognitive deficits. Mechanistically, PARP1 deficiency decreased amyloid precursor protein (APP) and BACE1 levels, altered γ-secretase complex composition, and enhanced Aβ degradation via neprilysin. These findings position PARP1 as a critical mediator of Aβ toxicity and neurodegeneration, suggesting its inhibition as a promising therapeutic strategy for AD. Significance Statement Our study identifies poly(ADP-ribose) (PAR) as an elevated biomarker in the cerebrospinal fluid of patients with mild cognitive impairment and Alzheimer’s disease, correlating with established markers of amyloid pathology. We demonstrate that PARP1, the enzyme responsible for PAR synthesis, is activated by neurotoxic Aβ 1-42 and mediates neuronal death, amyloid plaque formation, neuroinflammation, and cognitive deficits in a mouse model of AD. Importantly, genetic ablation of PARP1 not only protects neurons from Aβ toxicity but also reduces amyloid burden by suppressing Aβ production and enhancing its degradation. These findings highlight PARP1 as a critical regulator of amyloid pathology and neurodegeneration, and suggest that PARP1 inhibition may offer a promising therapeutic avenue for Alzheimer’s disease by simultaneously targeting multiple pathogenic mechanisms.

Year:

2025

Reactive oxygen and nitrogen species (RONS) are implicated in neurodegeneration, but their specific pathogenic roles remain unclear. Here, we developed a pair of iridium-based nanozymes with opposing functionalities to dissect these pathways. We show that a copper-tuned iridium nanozyme (Ir□Cu), despite being a superior ROS scavenger, paradoxically and dramatically exacerbated α-synuclein (αSyn) pathology in vivo . This pathology was causally linked to its ability to amplify RNS, as pharmacological inhibition of nitric oxide synthase (NOS) with L-NAME completely abrogated the pathology and reversed a human Parkinson’s disease (PD)-like transcriptomic signature. In contrast, a copper-free, broad-spectrum RONS-scavenging iridium (Ir) nanozyme demonstrated substantial therapeutic efficacy across diverse brain-first, body-first, and Alzheimer’s disease with Lewy body co-pathology models. Our findings uncover the importance of the RNS pathway in driving α-synucleinopathies and establish a critical design principle for nanomedicine, mandating caution in the use of redox-active copper for neuroprotective applications.

Year:

2025

Background Parkinson’s disease (PD) is a progressive neurodegenerative disorder involving impaired bioenergetics and mitochondrial dysfunction. Creatine (Cr) supplementation has been suggested as a pathophysiology-targeted therapy, yet human studies have yielded heterogeneous results. This study employs guanidino chemical exchange saturation transfer (GuanCEST) magnetic resonance imaging (MRI), a novel Cr-weighted imaging technique, to evaluate Cr level changes in patients with PD (PwPD) compared to healthy controls (HCs). Methods 25 PwPD and 24 age- and sex-matched HCs underwent standardized clinical assessments and GuanCEST MRI. Region-of-interest (ROI) and voxel-wise analyses were conducted to assess group differences. Kendall’s correlation and ANCOVA were used to explore associations between GuanCEST signals, disease presence, and clinical severity. Results GuanCEST signals in the caudate nucleus were significantly lower in PwPD (1.67 ± 0.26%) than in HCs (1.82 ± 0.16%; p = 0.023). Signal reduction correlated with increasing PD severity, particularly in thalamic subregions. In the internal medullary lamina, GuanCEST values negatively correlated with MDS-UPDRS-III scores (r = −0.44, p = 0.03) and a trend was also seen in the lateral thalamic nuclei (r = −0.39, p = 0.06). ANCOVA indicated GuanCEST values in the internal medullary lamina decreased by ∼0.01% per point increase in MDS-UPDRS-III (p = 0.007), adjusted for age and sex. Conclusion GuanCEST MRI shows promise as a non-invasive tool for detecting Cr alterations in PD. This technique may enhance our understanding of Cr metabolism in PD and support the development of targeted therapeutic strategies.

Year:

2025

The APOE gene is a major genetic determinant of neurovascular and immune function, yet the mechanisms by which its isoforms modulate brain vulnerability to pathogenic stress remain incompletely understood. Here, we employ isogenic human iPSC-derived immune vascularized Forebrain Organoid-based Multicellular Assembled Cerebral Organoids (FORMA COs) to dissect isoform-specific responses to a clinically relevant viral challenge. We find that APOE2 and APOE4 FORMA-COs exhibit heightened viral RNA burden and distinct neuroinflammatory profiles compared to APOE3. Specifically, APOE4 promotes IL-1α and VEGFA induction, whereas APOE2 leads to elevated TNFβ and VEGFA protein accumulation, indicating divergent pathways of injury. Integrated transcriptomic analyses, combined with known and predicted APOE protein protein interaction networks, reveal genotype dependent enrichment of cytokine signaling, angiogenic remodeling, and immune dysregulation. In vivo validation using humanized mouse models corroborates APOE genotype specific vascular remodeling, microglial activation, and oligodendrocyte perturbation. These findings demonstrate that APOE genotype confers context-specific susceptibility to neuroimmune and vascular injury, providing insight into genetic risk mechanisms underlying infection-related and neurodegenerative brain disorders.

Year:

2025

The specification and maintenance of human forebrain neural progenitor cells (NPCs) depend on both intrinsic gene networks and spatially localized niche signals, but the interplay between these cues remains incompletely understood. Here, we identify a spatially organized, paracrine IGF1 signaling architecture that regulates human FOXG1⁺ NPCs through multilayered transcriptional and translational control. Using a pluripotent stem cell–derived forebrain model, we show that FOXG1⁺ NPCs express IGF1 receptors but lack endogenous IGF1, instead depending on neighboring epithelial-like domains that secrete IGF1. IGF1 promotes progenitor proliferation, clonal expansion, and vertical tissue growth by activating PI3K–AKT–mTOR and MEK–ERK pathways. Ribosome profiling and 5′UTR reporter assays reveal that mTOR signaling selectively enhances translation of neurodevelopmental and biosynthetic transcripts— including GSX1 , a ventral fate determinant implicated in interneuron specification and autism. These findings uncover a human-specific regulatory mechanism in which spatially restricted IGF1–mTOR signaling integrates niche signals with translational output to support progenitor identity, biosynthetic capacity, and developmental resilience.

Year:

2025

This study presents a transcriptomic analysis of the cingulate cortex (CING) in Parkinson’s disease (PD) and Parkinson’s disease dementia (PDD) using a High-efficiency single-nucleus RNA sequencing (HiF-snRNA-seq) protocol optimized for post-mortem brain samples. RNA quality prediction, poly-A tailing, and dCas9-targeted depletion enabled analysis of 77 high-quality samples from 240 cases, yielding over 2 million nuclei classified into seven major cell types. Disease conditions revealed altered astrocyte and microglia proportions, implicating their roles in neuroinflammation. Differential expression analysis identified unique and shared genes across PD and PDD, linked to synaptic remodeling, stress responses, and inflammation. Stage-specific analysis uncovered tau-dependent early-stage genes and inflammation-associated late-stage genes. This study highlights the CING’s central role in PD and PDD pathophysiology, offering insights into disease mechanisms and identifying candidate genes and pathways for therapeutic and biomarker development.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (13)

Sanjay K Jain

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Benjamin François Combes

University of Zurich

SWITZERLAND
View details

Jinchong Xu

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Ramhari Kumbhar

Research associate

Johns Hopkins University School of Medicine

UNITED STATES
View details

Valina Dawson

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Chan Hyun Na

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Nikolay Bliznyuk

University of Florida

UNITED STATES
View details

Tae-In Kam

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Hanseok Ko

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Olga Pletnikova

Research Associate Professor

University at Buffalo Jacobs School of Medicine and Biomedical Sciences

UNITED STATES
View details

Xiaobo Mao

Associate Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Juan C Troncoso

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Ruiqing Ni

University of Zurich

SWITZERLAND
View details